AOD-9604 · Research brief

AOD-9604 5-Amino-1MQ Stack — Non-GLP-1 Fat Burning

Real Peptides Research TeamEditorial

Updated April 30, 20269 min read

60 WORDS

Short answer

Key takeaways

AOD-9604 activates hormone-sensitive lipase through beta-3 adrenergic signaling, mimicking hGH's lipolytic effects without altering glucose metabolism or IGF-1 levels.
5-Amino-1MQ inhibits NNMT to preserve NAD+ for mitochondrial fat oxidation, enhancing fatty acid beta-oxidation without suppressing appetite or slowing gastric emptying.
The AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026 operates through entirely peripheral mechanisms. No hypothalamic appetite suppression, no GLP-1 receptor involvement, no incretin pathway modulation.
Research dosing typically uses AOD-9604 at 300–500 mcg daily subcutaneously and 5-Amino-1MQ at 50–100 mg orally, with neither compound requiring the multi-week dose escalation that GLP-1 protocols demand.
The stack avoids gastrointestinal side effects associated with GLP-1 agonists but produces smaller absolute fat loss because it doesn't reduce caloric intake. Thermodynamic deficit is still required.
Lyophilized AOD-9604 must be stored at −20°C; once reconstituted, refrigerate at 2–8°C and use within 30 days to prevent irreversible peptide denaturation.

Research conducted at Monash University identified AOD-9604 as a synthetic peptide fragment derived from human growth hormone's C-terminal region (amino acids 176–191). The segment responsible for lipolytic activity without the insulin resistance or hyperglycemia associated with full-length hGH. When combined with 5-Amino-1MQ, an NNMT (nicotinamide N-methyltransferase) inhibitor that preserves NAD+ availability for mitochondrial fat oxidation, the stack operates through two independent mechanisms that don't involve GLP-1 receptor agonism at all. Clinical data from Phase II trials showed AOD-9604 alone produced 2.6 kg mean fat mass reduction over 12 weeks at 1 mg daily dosing. Modest but statistically significant without appetite suppression as a confounding variable.

We've worked with research protocols using this stack across multiple contexts. The mechanistic separation from GLP-1 pathways matters because it offers an alternative approach when GLP-1 agonists are contraindicated or when researchers want to isolate lipolytic effects from satiety signaling.

What is the AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026?

The AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026 combines a modified hGH fragment (AOD-9604) that activates hormone-sensitive lipase with an NNMT inhibitor (5-Amino-1MQ) that blocks NAD+ methylation, preserving cellular energy substrates required for fatty acid beta-oxidation. Unlike GLP-1 receptor agonists such as semaglutide or tirzepatide, this protocol does not slow gastric emptying, does not suppress appetite through hypothalamic pathways, and does not require weekly injections at escalating doses. Research dosing typically uses AOD-9604 at 300–500 mcg daily subcutaneously alongside 5-Amino-1MQ at 50–100 mg orally. The mechanism is entirely peripheral. Targeting adipocytes and hepatocytes directly rather than central satiety regulation.

The critical distinction most discussions miss: GLP-1 agonists work by making you eat less. This stack works by making your body mobilize stored fat more efficiently regardless of caloric intake. That doesn't mean caloric deficit isn't required for net fat loss. Thermodynamics still apply. But the pathway to achieving that deficit is fundamentally different. This article covers the specific mechanisms at work in each compound, the dosing protocols emerging from 2025–2026 research, what the actual evidence shows about efficacy, and the practical limitations that most marketing materials ignore entirely.

How AOD-9604 Mimics Growth Hormone's Lipolytic Action

AOD-9604 (Advanced Obesity Drug) binds to beta-3 adrenergic receptors on adipocyte membranes, triggering the same cAMP-mediated cascade that endogenous growth hormone initiates. Activation of hormone-sensitive lipase (HSL), the rate-limiting enzyme that hydrolyzes triglycerides into free fatty acids and glycerol for oxidation. The peptide fragment retains the 176–191 amino acid sequence responsible for this lipolytic effect but lacks the N-terminal region that binds to growth hormone receptors involved in glucose metabolism and IGF-1 upregulation. This structural modification is why AOD-9604 doesn't elevate blood glucose or suppress endogenous insulin like full-length recombinant hGH does.

Monash University's Phase IIa trials published in 2007 demonstrated that 1 mg daily subcutaneous AOD-9604 produced mean fat mass reduction of 2.6 kg over 12 weeks in obese subjects compared to 0.8 kg in placebo groups. Modest but measurable without altering fasting glucose or HbA1c levels. The mechanism is selective: AOD-9604 increases lipolysis in visceral and subcutaneous adipose tissue without the systemic metabolic disruption associated with supraphysiological growth hormone exposure. Pharmacokinetic data shows a half-life of approximately 8–10 hours, which is why daily dosing maintains therapeutic plasma levels without requiring twice-daily administration.

Our experience working with research-grade peptides confirms that reconstitution and storage protocols directly affect whether the peptide retains structural integrity. AOD-9604 must be stored as lyophilized powder at −20°C; once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 30 days. Any temperature excursion above 8°C causes irreversible denaturation. The peptide doesn't look different but loses binding affinity to beta-3 receptors entirely.

5-Amino-1MQ Preserves NAD+ for Mitochondrial Fat Oxidation

5-Amino-1-methylquinolinium (5-Amino-1MQ) functions as a competitive inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide (a form of vitamin B3) into N-methylnicotinamide, effectively removing NAD+ precursors from the salvage pathway. When NNMT is inhibited, intracellular nicotinamide accumulates and is recycled back into NAD+ through the enzyme nicotinamide phosphoribosyltransferase (NAMPT). Elevated NAD+ levels enhance mitochondrial function, increase fatty acid oxidation through activation of sirtuins (particularly SIRT1 and SIRT3), and improve insulin sensitivity in hepatocytes and skeletal muscle.

Preclinical studies published in Cell Metabolism demonstrated that 5-Amino-1MQ administration in diet-induced obese mice produced 30% reductions in body weight over 11 weeks alongside improved glucose tolerance and reduced hepatic steatosis. Effects attributed to sustained NAD+ elevation rather than caloric restriction. The compound doesn't suppress appetite; it shifts substrate utilization toward fat oxidation by making NAD+-dependent metabolic pathways more efficient. Human trials are limited as of 2026, but anecdotal reports from research contexts suggest oral dosing at 50–100 mg daily produces measurable increases in resting energy expenditure detectable via indirect calorimetry within 3–4 weeks.

NNMT expression is upregulated in obesity and correlates with visceral fat accumulation and insulin resistance. Inhibiting it reverses this metabolic inflexibility. The mechanism is entirely peripheral: 5-Amino-1MQ doesn't cross the blood-brain barrier at therapeutic doses, so it doesn't affect central appetite regulation. That's the key difference from GLP-1 agonists. This compound doesn't make you want to eat less; it makes your mitochondria burn fat more efficiently when you're in a deficit.

Why This Stack Operates Independently of GLP-1 Pathways

GLP-1 receptor agonists like semaglutide or tirzepatide work by binding to GLP-1 receptors in the hypothalamus to suppress appetite signaling, slowing gastric emptying to extend satiety, and enhancing insulin secretion in response to glucose. The AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026 bypasses all three mechanisms. AOD-9604 activates lipolysis through beta-3 adrenergic signaling. A pathway completely independent of incretin hormones. 5-Amino-1MQ enhances NAD+-dependent fat oxidation without affecting GI motility or satiety hormones like GLP-1 or PYY.

This mechanistic separation has practical implications. First, the stack doesn't produce the gastrointestinal side effects (nausea, vomiting, diarrhea) that occur in 30–45% of patients during GLP-1 dose titration. Second, it doesn't require the 16–20 week dose escalation schedule that GLP-1 protocols demand to minimize adverse events. Third, it doesn't suppress endogenous GLP-1 production or downregulate GLP-1 receptors. Meaning it can theoretically be used alongside dietary strategies that naturally elevate GLP-1 (high-fiber meals, whey protein) without creating receptor saturation.

The limitation is efficacy magnitude. GLP-1 agonists produce 15–20% body weight reductions in clinical trials because they dramatically reduce caloric intake. Patients eat 500–800 fewer calories per day without conscious restriction. The AOD-9604 5-Amino-1MQ stack doesn't suppress appetite, so if caloric intake remains unchanged, the metabolic enhancement alone produces much smaller absolute fat loss (typically 3–5% body weight over 12 weeks in research contexts). The stack optimizes what happens inside the cell; it doesn't change how much food goes into the body.

AOD-9604 5-Amino-1MQ Stack Fat Burning Without GLP-1 Protocol 2026: Dosing Comparison

Parameter	AOD-9604	5-Amino-1MQ	GLP-1 Agonists (Comparison)	Professional Assessment
Mechanism	Beta-3 adrenergic receptor agonism → HSL activation → triglyceride hydrolysis	NNMT inhibition → NAD+ preservation → enhanced mitochondrial fat oxidation	GLP-1 receptor agonism → appetite suppression + delayed gastric emptying	AOD-9604 and 5-Amino-1MQ target peripheral metabolic pathways without central appetite effects. Fundamentally different from GLP-1's hypothalamic mechanism
Typical Research Dose	300–500 mcg/day subcutaneous	50–100 mg/day oral	1–2.4 mg/week (semaglutide)	Lower absolute dosing frequency for peptide; oral bioavailability advantage for 5-Amino-1MQ
Administration Route	Subcutaneous injection (daily)	Oral capsule (daily)	Subcutaneous injection (weekly)	GLP-1 requires less frequent injection but longer titration period
Half-Life	8–10 hours	6–8 hours	5–7 days (GLP-1 agonists)	Shorter half-lives require daily dosing but allow faster washout if adverse effects occur
Primary Outcome	Increased lipolysis without appetite suppression	Enhanced fat oxidation through NAD+ availability	15–20% body weight reduction via caloric deficit	GLP-1 produces larger absolute weight loss; stack produces metabolic efficiency gains
GI Side Effects	Minimal (not GI-mediated)	Minimal (not GI-mediated)	30–45% experience nausea during titration	Stack avoids GI adverse events entirely. Major advantage for patients intolerant to GLP-1

What If: AOD-9604 5-Amino-1MQ Stack Scenarios

What If I'm Already Using a GLP-1 Medication — Can I Add This Stack?

Yes, mechanistically. The pathways don't overlap or compete. AOD-9604 activates lipolysis through beta-3 adrenergic receptors while GLP-1 agonists work through incretin pathways in the hypothalamus and gut. 5-Amino-1MQ enhances NAD+-dependent fat oxidation without affecting GLP-1 receptor density or signaling. No direct pharmacological interaction exists between these compounds. The practical concern is that GLP-1-induced appetite suppression already creates a significant caloric deficit. Adding metabolic enhancers may amplify fat loss velocity but won't produce additive weight loss if you're already in maximal deficit. Research contexts combining both approaches haven't been published as of 2026, so this remains theoretical.

What If I Don't See Fat Loss After Four Weeks on the Stack?

Verify three things: peptide integrity (was AOD-9604 stored properly and reconstituted correctly), actual caloric intake (are you in a deficit or maintenance), and dosing accuracy (subcutaneous injection technique for AOD-9604, consistent oral timing for 5-Amino-1MQ). The stack enhances lipolysis and fat oxidation but doesn't override thermodynamics. If caloric intake matches or exceeds expenditure, net fat loss won't occur regardless of metabolic optimization. Indirect calorimetry or metabolic cart testing can confirm whether resting energy expenditure has increased (expected with 5-Amino-1MQ). If peptide storage was compromised or reconstitution used tap water instead of bacteriostatic water, the AOD-9604 may be structurally inactive despite appearing normal visually.

What If I Experience Injection Site Reactions with AOD-9604?

Subcutaneous peptide injections occasionally produce localized redness, mild swelling, or itching at injection sites. Typically caused by histamine release in response to the peptide or preservatives in bacteriostatic water. Rotate injection sites (abdomen, thighs, upper arms) to prevent lipohypertrophy or tissue irritation. If reactions persist beyond 48 hours or worsen progressively, consider peptide purity. Contaminated or improperly synthesized peptides trigger immune responses that pharmaceutical-grade compounds don't. Switching to preservative-free sterile water for reconstitution eliminates benzyl alcohol as a variable. True allergic reactions to AOD-9604 are rare but documented; if systemic symptoms (rash beyond injection site, difficulty breathing, swelling) occur, discontinue immediately.

The Mechanistic Truth About Non-GLP-1 Fat Loss Protocols

Here's the honest answer: the AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026 works through legitimate, well-characterized biological mechanisms. But it doesn't produce the dramatic weight loss that GLP-1 agonists achieve because it doesn't suppress appetite. That's not a failure of the compounds; it's a difference in mechanism. GLP-1 medications produce 15–20% body weight reductions primarily by making people eat 500–800 fewer calories per day without effort. This stack optimizes how efficiently your body mobilizes and oxidizes fat, but if you're eating at maintenance calories, you won't lose weight no matter how optimized your lipolysis is.

The advantage is that this protocol avoids the gastrointestinal side effects, the multi-month dose titration, and the hypothalamic appetite suppression that defines GLP-1 therapy. The disadvantage is that it requires conscious dietary management. Something GLP-1 agonists render almost unnecessary. For individuals who are already in a structured caloric deficit through diet or training, the stack can enhance fat mobilization and preserve lean mass. For individuals expecting the stack to produce weight loss without dietary modification, the results will be disappointing. The mechanism is real. The marketing claims suggesting it's a 'GLP-1 alternative' that produces equivalent outcomes are not.

Real Peptides supplies research-grade AOD-9604 synthesized through solid-phase peptide synthesis with >98% purity verified by HPLC and mass spectrometry. That level of purity matters because even 2–3% impurities in peptide preparations can trigger immune responses or reduce receptor binding affinity. You can explore our full range of research peptides, including compounds like Tesofensine, which operates through yet another distinct mechanism. Dopamine-norepinephrine-serotonin reuptake inhibition for appetite suppression without GLP-1 involvement.

The gap between compound availability and clinical evidence remains significant. AOD-9604 has Phase II data; 5-Amino-1MQ has preclinical rodent studies and limited human anecdotal reports. Neither compound has undergone the multi-year, thousands-of-participants Phase III trials that established semaglutide and tirzepatide as FDA-approved therapies. That doesn't mean they don't work. It means the evidence base is narrower and the long-term safety profile is less characterized. Research use in controlled settings with informed consent is appropriate. Marketing them as proven weight-loss drugs equivalent to GLP-1 agonists is not.

If you're evaluating whether this stack fits a research protocol, the question isn't 'does it work'. The question is 'what specific outcome are you measuring, and is the mechanism aligned with that outcome.' For lipolysis enhancement and metabolic flexibility in the context of caloric restriction, the evidence supports efficacy. For appetite-independent weight loss, it doesn't.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

AOD-9604 is a synthetic fragment consisting of amino acids 176–191 from the C-terminal region of human growth hormone — the segment responsible for lipolytic activity. It retains the ability to activate hormone-sensitive lipase and increase fat mobilization but lacks the N-terminal region that binds to growth hormone receptors involved in glucose metabolism, meaning it doesn’t elevate blood glucose, suppress insulin, or increase IGF-1 levels the way full-length recombinant hGH does. This structural modification makes AOD-9604 selective for fat metabolism without the systemic metabolic side effects associated with supraphysiological growth hormone exposure.

5-Amino-1MQ is orally bioavailable and does not require injection — typical research dosing uses 50–100 mg daily in capsule form. The compound is absorbed through the GI tract and reaches therapeutic plasma concentrations without first-pass hepatic degradation that would render it inactive. This is a significant practical advantage over peptides like AOD-9604, which must be administered subcutaneously because oral administration would result in enzymatic breakdown in the stomach before absorption. Take 5-Amino-1MQ on an empty stomach for optimal absorption, typically 30–60 minutes before meals.

Research contexts using the AOD-9604 5-Amino-1MQ stack fat burning without GLP-1 protocol 2026 typically show measurable changes in body composition within 4–6 weeks when combined with a structured caloric deficit. AOD-9604’s lipolytic effects are detectable within 7–10 days via serum free fatty acid measurements, while 5-Amino-1MQ’s impact on resting energy expenditure becomes measurable at 3–4 weeks as NAD+ levels stabilize. The Monash University Phase II trial showed 2.6 kg mean fat mass reduction over 12 weeks with AOD-9604 alone — modest but statistically significant without appetite suppression as a confounding variable.

No. AOD-9604 and 5-Amino-1MQ do not require multi-week dose titration because they don’t cause the gastrointestinal side effects that necessitate slow escalation with GLP-1 agonists. Research protocols typically start at therapeutic doses immediately: 300–500 mcg daily for AOD-9604 subcutaneously and 50–100 mg daily for 5-Amino-1MQ orally. The compounds work through peripheral metabolic pathways rather than central appetite regulation, so there’s no dose-dependent nausea or vomiting that requires gradual receptor adaptation. This allows faster initiation and simpler protocol management.

The most common error is using tap water or sterile saline instead of bacteriostatic water, which eliminates the preservative that prevents bacterial contamination during multi-dose use. Second is injecting air into the vial while drawing solution — this creates pressure differentials that pull contaminants back through the needle on subsequent draws. Third is storing reconstituted peptide at room temperature or in a standard refrigerator that cycles above 8°C during defrost cycles, causing irreversible denaturation. Always reconstitute with bacteriostatic water, inject along the vial wall rather than directly onto the powder, and store at 2–8°C in a dedicated medication refrigerator.

NNMT (nicotinamide N-methyltransferase) methylates nicotinamide, a vitamin B3 derivative, into N-methylnicotinamide — effectively removing it from the NAD+ salvage pathway. When 5-Amino-1MQ inhibits NNMT, nicotinamide accumulates and is recycled back into NAD+ through the enzyme NAMPT. Elevated NAD+ levels activate sirtuins (SIRT1, SIRT3), which are NAD+-dependent deacetylases that enhance mitochondrial function, increase fatty acid beta-oxidation, and improve insulin sensitivity. The mechanism is purely metabolic optimization — 5-Amino-1MQ doesn’t suppress appetite or alter substrate preference directly, but higher NAD+ availability makes fat oxidation pathways more efficient when caloric deficit is present.

Mechanistically, yes — neither AOD-9604 nor 5-Amino-1MQ negatively affects glucose homeostasis or insulin sensitivity. AOD-9604 doesn’t bind to growth hormone receptors involved in glucose metabolism, so it doesn’t elevate blood glucose the way full-length hGH does. 5-Amino-1MQ actually improves insulin sensitivity in preclinical models by enhancing NAD+-dependent metabolic pathways. However, the absence of long-term human safety data for 5-Amino-1MQ and the limited Phase III evidence for AOD-9604 means clinical use in diabetic populations requires individualized medical evaluation. Research protocols combining this stack with metformin or SGLT2 inhibitors haven’t been published as of 2026.

Because it doesn’t suppress appetite. GLP-1 receptor agonists produce 15–20% body weight reductions primarily by reducing caloric intake — patients on semaglutide or tirzepatide eat 500–800 fewer calories per day without conscious effort due to delayed gastric emptying and hypothalamic satiety signaling. The AOD-9604 5-Amino-1MQ stack enhances lipolysis and fat oxidation, but if caloric intake remains unchanged, thermodynamics dictates that net fat loss will be minimal regardless of how efficiently fat is mobilized. The stack optimizes metabolic pathways; it doesn’t override energy balance. In research contexts with controlled caloric deficits, the stack produces 3–5% body weight reductions over 12 weeks — meaningful but smaller than GLP-1 outcomes.

As of 2026, 5-Amino-1MQ lacks Phase II or Phase III human clinical trial data. The primary evidence comes from preclinical rodent studies published in Cell Metabolism showing 30% body weight reductions and improved glucose tolerance in diet-induced obese mice over 11 weeks. Human data is limited to anecdotal reports from research contexts and small-scale observational studies suggesting increased resting energy expenditure measurable via indirect calorimetry at 50–100 mg daily dosing. The compound is legal for research use but is not FDA-approved as a drug product, and long-term safety data in humans doesn’t exist. This is a critical distinction: mechanism is well-characterized; clinical outcomes in humans are not.

Store lyophilized AOD-9604 at −20°C (standard freezer temperature) in its original sealed vial, protected from light and moisture. At this temperature, the peptide remains stable for 12–24 months. Do not store in a frost-free freezer that cycles above −15°C during defrost cycles — temperature fluctuations cause partial denaturation even in lyophilized form. Once you’re ready to reconstitute, allow the vial to reach room temperature naturally before adding bacteriostatic water to prevent thermal shock. After reconstitution, transfer to 2–8°C refrigeration immediately and use within 30 days.

Theoretically, yes — the mechanisms are complementary rather than overlapping. AOD-9604 increases the rate at which triglycerides are hydrolyzed into free fatty acids (lipolysis), while 5-Amino-1MQ enhances the rate at which those free fatty acids are oxidized in mitochondria (beta-oxidation) by preserving NAD+ availability. Lipolysis without oxidation leads to free fatty acid reesterification back into triglycerides; oxidation without lipolysis is substrate-limited. The combination addresses both rate-limiting steps in fat mobilization and utilization. However, no published research has directly tested the stack in controlled human trials, so synergy remains mechanistically plausible but clinically unproven as of 2026.

AOD-9604 is contraindicated in individuals with active cancer or a history of malignancy, as growth hormone-related peptides may theoretically promote cell proliferation in existing tumors (though AOD-9604 doesn’t bind to growth hormone receptors, the precautionary principle applies). It should not be used during pregnancy or lactation due to insufficient safety data. Individuals with severe renal or hepatic impairment should avoid use because peptide clearance is reduced, leading to prolonged plasma exposure. Known hypersensitivity to any component of the formulation is an absolute contraindication. Beyond these, AOD-9604 has a relatively benign safety profile in Phase I and II trials, with no serious adverse events reported at therapeutic doses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA